Journal of Jilin University(Medicine Edition) ›› 2019, Vol. 45 ›› Issue (04): 965-970.doi: 10.13481/j.1671-587x.20190440
• Review • Previous Articles Next Articles
Research progress in PD-1/PD-L1 immune checkpoint inhibitors in treatment of non-smallcell lung cancer
-
Received:2018-09-21Online:2019-07-28Published:2019-08-02
CLC Number:
- R734.2
Cite this article
share this article
| [1] ISHIDA Y, AGATA Y, SHIBAHARA K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895. [2] HE J, HU Y, HU M, et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J]. Sci Rep, 2015, 5:13110. [3] MEYERS D E, BRYAN P M, BANERJI S, et al. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer[J]. Curr Oncol, 2018, 25(4):324-334. [4] CEERAZ S, NOWAK E C, NOELLE R J. B7 family checkpoint regulators in immune regulation and disease[J]. Trends Immunol, 2013, 34(11):556-563. [5] FIFE B, BLUESTONE J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J]. Immunol Rev, 2008, 224:166-182. [6] MAMALIS A, GARCHA M, JAGDEO J. Targeting the PD-1 pathway:a promising future for the treatment of melanoma[J]. Arch Dermatol Res, 2014, 306(6):511-519. [7] LIANG S C, LATCHMAN Y E, BUHLMANN J E, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol, 2003, 33(10):2706-2716. [8] LI XL, SHAO CS, SHI YF, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy[J]. J Hematol Oncol, 2018, 11(1):31. [9] THOMPSON R H, GILLETT M D, CHEVILLE J C, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma[J]. Cancer, 2005, 104(10):2084-2091. [10] TAUBE J M, ANDERS R A, YOUNG G D, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Translk Med, 2012, 4(127):127ra37. [11] DONG H, ZHU G, TAMADA K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12):1365-1369. [12] HIRANO F, KANEKO K, TAMURA H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity[J]. Cancer Res, 2005, 65(3):1089-1096. [13] DONG H, STROME S E, SALOMAO D R, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8):793-800. [14] TOPALIAN S L, TAUBE J M, ANDERS R A, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16(5):275-287. [15] CARBOGNIN L, PILOTTO S, MILELLA M, et al. Differential Activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1(PD-L1):sensitivity analysis of trials in melanoma, lung and genitourinary cancers[J]. PLoS One, 2015, 10(6):e0130142. [16] MA W J, GILLIGAN B M, YUAN J D, et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy[J]. J Hematol Oncol, 2016, 9(1):47-67. [17] RECK M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer[J]. Immunotherapy, 2018, 10(2):93-105. [18] LI J, JIE H B, LEI Y, et al. PD-1/SHP-2 inhibit Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment[J]. Cancer Res, 2015, 75(3):508-518. [19] SZNOL M, CHEN L. Antagonist antibodies to PD-1 and B7-H1(PD-L1) in the treatment of advanced human cancer:response[J]. Clin Cancer Res, 2013, 19(19):5542. [20] JUNEJA V R, MCGUIRE K A, MANGUSO R T, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity[J]. J Exp Med, 2017, 214(4):895-904. [21] TOPALIAN SL, HODI FS, BRAHMER JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454. [22] GETTINGER S N, HORN L, GANDHI L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 33(18):2004-2012. [23] GETTINGER S, HORN L, JACKMAN D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J]. J Clin Oncol, 2018, 36(17):1675-1684. [24] RIZVI N A, MAZIÈRES J, PLANCHARD D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265. [25] HORN L, SPIGEL D R, VOKES E E, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer:Two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35):3924-3933. [26] FONT E F, GETTINGER S N, BURGIO M A, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057):3-year update and outcomes in patients with liver metastases[J]. Ann Oncol, 2018, 29(4):959-965. [27] WU Y, LU S, CHENG Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC):results of the phase 3 CheckMate 078 study[C]. Chicago:AACR Annual Meeting, 2018. [28] CARBONE D P, RECK M, PAZARES L, et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer[J]. N Engl J Med, 2017, 39(25):2415-2426. [29] HELLMANN M D, CIULEANU T E, PLUZANSKI A,et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104. [30] PAI-SCHERF L, BLUMENTHAL G M, LI H S, et al. FDA approval summary:pembrolizumab for treatment of metastatic non-small cell lung cancer:first-line therapy and beyond[J]. Oncologist, 2017, 22(11):1392-1399. [31] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550. [32] HUI R, GARON E B, GOLDMAN J W, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:a phase 1 trial[J]. Ann Oncol, 2017, 28(4):874-881. [33] BORGHAEI H, LANGER C J, GADGEEL S, et al.24-Month overall survival from KEYNOTE-021 cohort G:pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small-cell lung cancer[J]. J Thorac Oncol, 2019.14(1):124-129. [34] GANDHI L, RODRÍGUEZ-ABREUD,GADGEELS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092. [35] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051. [36] HERBST R S, SORIA J C, KOWANETZ M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528):563-567. [37] FEHRENBACHER L, SPIRA A, BALLINGER M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846. [38] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265. [39] SOCINSKI M A, JOTTE R M, CAPPUZZO F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. [40] JOTTE R M, CAPPUZZO F,VYNNYCHENKO L, et al. IMpower131:Primary PFS and safety analysis of a randomized phase Ⅲ study of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitacel as 1L therpay in advanced squamous NSCLC[J]. J Clin Oncol, 2018, 36(Suppl 18):LBA 9000. [41] JIANG L Y, SU X Y, ZHANG T W, et al. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)[J]. Oncotarget, 2017, 8(16):26845-26857. [42] HIRSCH F R, MCELHINNY A, STANFORTH D, et al. PD-L1 immunohistochemistry assays for lung cancer:results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2):208-222. [43] MCLAUGHLIN J, HAN G, SCHALPER K A, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(1):46-54. [44] HAUSE R J, PRITCHARD C C, SHENDURE J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nat Med, 2016, 22(11):1342-1350. [45] RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128. |
| [1] | Xin LIU,Yuyang ZHANG,Deling ZENG,Xiaoqin LIU,Lu ZHANG,Meiying LI,Hong CHEN,Bangrong CAO,Shiqi MA. Levels of KLRG1 +NK cells in peripheral blood of NSCLC patients and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 746-754. |
| [2] | Qiaotong REN,Weihua WU,Xingxiang WANG,Shichao WANG,Yipeng CHENG,Chun LI. Effect of interleukin-17 recepter B gene silencing on proliferation, invasion and apoptosis of lung adenocarcinoma A549 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 738-745. |
| [3] | Yang LI,Shiyang LI,Hongmei ZHANG,Qianqian LIU,Yubing CHEN. Effect of NGFR gene expression differences on promotion of apoptosis of squamous cell carcinoma and adenocarcinoma cells by PD-1 inhibitor-activated T lymphocytes [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 680-693. |
| [4] | Lei TANG,Peinan LIN,Ling ZHANG,Haiyan XU,Fengchun ZHANG. Chemotherapy efficacy and plasma drug concentration changes in patient with limited-stage small cell lung cancer complicated with uremia: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1687-1694. |
| [5] | Xiaoshuang HE,Lina XU,Mei CUI,Yu ZHAO,Bei WANG,Zheng HUANG,Yuchao WANG,Wenyan XIN,Chao WU. Effects of lncRNA DUXAP8 in lung cancer A549 cells-derived exosomes on lung cancer cell growth and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 958-967. |
| [6] | Xingxiang WANG,Ying ZHAO,Qiaotong REN,Hefei WANG,Gang PU,Chun LI. Promotive effect of M2 macrophages on epithelial-mesenchymal transition and cisplatin resistance in non-small cell lung cancer A549 cells by regulating NF-κB signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 642-652. |
| [7] | Yihui WANG,Qing ZHANG,Yingnan LI,Liping YE. Effect of KIAA1522 on proliferation, migration, and invasion of lung cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 727-739. |
| [8] | Congcong BAI,Xianlei ZHOU,Zhi ZHANG,Shuang GAO,Xuemei ZHANG. Expression of CSPG4P12 gene in small cell lung cancer tissue and its effect on behaviors of cell biology [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 392-402. |
| [9] | Bo LIU,Chao SUN,Xu WANG,Kewei MA. Bioinformatics analysis on differentially expressed genes in multiple primary lung cancers based on GEO database [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 437-446. |
| [10] | Xiaoming WANG,Xueye WANG. Invasive adenocarcinoma of lung complicated with metastatic NUT midline carcinoma of mediastinal lymph node： A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 825-830. |
| [11] | Aihua REN,Yanbo DONG,Runzhi MIAO,Yujiao LYU,Yanfeng LIU. Effect of ganoderic acid A on glycolysis and its key rate-limiting enzymes of non-small cell lung cancer PC9 cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 682-688. |
| [12] | Yuan WANG,Zhijuan WANG,Mingshu ZHANG,Yihui WANG,Qing ZHANG,Liping YE. Effects of monocyte chemoattractant protein-1 on invasion and migration of lung cancer A549 and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 666-675. |
| [13] | Zongjun CHEN,Yahong CHEN,Liyun HUANG,Ziying LIANG. Effects of genomic instability and MYC gene mutation of non-small cell lung cancer A549 cells on resistance of gemcitabine [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 355-363. |
| [14] | Aihua REN,Xinda JU,Aofei LIU,Yongchao LIU,Yanfeng LIU. Effect of ganoderic acid A on proliferation and apoptosis of human non-small cell lung cancer PC-9 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1466-1472. |
| [15] | Xiaodong GAI,Ying ZHAO,Hefei WANG,Chengyuan HE,Xingxiang WANG,Chun LI. Regulatory effect of FOXP3 on chemosensitivity of non small-cell lung cancer A549 cells to doxorubicin and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1161-1167. |
|